Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novopharm Zantac patent challenge will focus on form 1 ranitidine following appeals court ruling.

Executive Summary

NOVOPHARM ZANTAC PATENT CHALLENGE WILL FOCUS ON FORM 1 RANITIDINE following an appeals court ruling April 21 upholding Glaxo's patent for form 2 ranitidine, the active ingredient in the anti-ulcer medication Zantac. The D.C. appeals court affirmed a Sept. 17, 1993 Elizabeth City, N.C. federal court ruling in favor of Glaxo in its patent infringement dispute with the Canadian generic manufacturer Novopharm ("The Pink Sheet" Sept. 20, 1993, T&G-1). Novopharm "will move forward with its plans to produce form 1 generic Zantac," the company declared.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026137

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel